Singapore Markets closed

Aadi Bioscience, Inc. (AADI)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
13.86-1.19 (-7.91%)
At close: 04:00PM EDT
13.86 0.00 (0.00%)
After hours: 04:00PM EDT

Aadi Bioscience, Inc.

17383 Sunset Boulevard
Suite A250
Pacific Palisades, CA 90272
United States
424 473 8055
https://aadibio.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees39

Key executives

NameTitlePayExercisedYear born
Dr. Neil P. Desai Ph.D.Founder, Pres, CEO, Sec. & Director1.23MN/A1965
Mr. Scott M. Giacobello CPACFO & Treasurer495.56kN/A1970
Mr. Brendan P. Delaney M.B.A.Chief Operating Officer491.65kN/A1975
Mr. Mitchall G. ClarkSr. VP of Regulatory Affairs & Quality AssuranceN/AN/A1961
Dr. Loretta M. Itri F.A.C.P., M.D.Chief Medical OfficerN/AN/A1950
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Corporate governance

Aadi Bioscience, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.